A cost-effective method to prepare pure vildagliptin

Letters in Organic Chemistry

Volumn 10, Issue 3, 2013, Pages 159-163

  Peng, Jun ^a   Feng, Yue ^a   Tao, Zhu ^a   Chen, Yingjie ^a   Hu, Xiangnan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cost effective; TCT; Vildagliptin

Indexed keywords

EID: 84879813850     PISSN: 15701786     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570178611310030003     Document Type: Article

References (16)

1. Deacon, C. F. Therapeutic strategies based on glucagon-like pep tide 1. Diabetes, 2004, 53, 2181-2189.
2. Chia. C. H.; Egan, J. M. Biology and therapeutic potential of GLP- 1 in the treatment of diabetes Drug Discovery Today: Disease Mechanisms, 2005, 2, 295-301.
3. Kieffer, T. J.; McIntosh, C. H.; Pederson, R. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 1995, 136, 3585-3596.
4. Ahren, B.; Simonsson, E.; Larsson, H.; Landin-Olsson, M.; Tor- geirsson, H.; Jansson, P. A.; Sandqvist, M.; Bavenholm, P.; Efendic, S.; WEriksson, J.; Dickinson, S.; Holmes, D. Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes. Diabetes Care, 2002, 25, 869-875.
5. Kim, D.; Wang, L. P.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H. B.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R. S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber. A. E. (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5, 6-dihydro[1, 2, 4]triazolo[4, 3-A]pyrazin- 7(8H)-yl]-1-(2, 4, 5-trifluorophenyl)butan-2-Amine:GA Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. J. Med. Chem., 2005, 48, 141-151.
6. Henness, S.; Keam, S. J. Vildagliptin. Drugs, 2006, 66, 1989-2001.
7. Dhillon, S.; Weber, J. Saxagliptin. Drugs, 2009, 69, 2103-2114.
8. Feng, J.; Zhang, Z. Y.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.; Kassel, D. B.; Navre, M.; Shi, L. H.; Skene, R. J.; Asakawa, T.; Takeuchi, K; Xu, R. D.; Webb, D. R.; Gwaltney, S. L. Discovery of Alogliptin:G A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IVhttp://pubs.acs.org/doi/abs/10.1021/jm070104l - jm070104lAF2#jm070104lAF2. J. Med. Chem., 2007, 50, 2297-2300.
9. Forst, T.; Uhlig-Laske, B.; Ring, A.; Graefe-Mody, U.; Friedrich, C; Herbach, K; Woerle, H. J.; Dugi, K. A. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. DIABETIC Medicine, 2010, 27, 1409-1419.
10. Villhauer, E. B. N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase- IV. U.S. Patent 6, 166, 063, December 26, 2000.
11. Singh, S. K; Manne, N.; Pal, M. Synthesis of (S)-1-(2- chloroacetyl)pyrrolidine-2-carbonitrile: A key intermediate for dipeptidyl peptidase IV inhibitors. Beilstein J. Org. Chem., 2008, 4, 1-5.
12. Manne, S.; Sajja, E.; Ghojala, V. R.; Bairy, K. R. Process for pre-papration of DPP- IV inhibitors. WO. Patent 2011/101861 A1, August 25, 2011.
13. Lin, Z. G.; Lv, H. J.; Zhao, F. Q. Derivatives of azabicyclo octane, the method of making them and uses thereof as inhibitors of dipeptidyl peptidase-IV. WO. Patent 0, 089, 636, July 31, 2008.
14. Rayle, H. L.; Fellmeth, L. Development of a Process for Triazine-Promoted Amidation of Carboxylic Acids. Organic Process Re-search & Development, 1999, 3, 172-176.
15. Venkataraman, K; Wagle, D. R. Cyanuric chloride: a useful reagent for converting carboxylic acids into chlorides, esters, amides and peptides. Tetrahedron Lettrrs, 1979, 20, 3037-3040.
16. Stephen, W. Process for preparing vildagliptin. WO. Patent 0, 084, 383, July 17, 2008.